Brain Network Articles & Analysis
9 news found
The Relivion DP is the first non-invasive, multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders. ...
” Relivion is a non-invasive brain neuromodulation device that is placed around the head and delivers stimulation to the occipital and trigeminal nerves. This creates a cumulative effect by releasing neurotransmitters in the brainstem and modulating brain networks associated with control of pain and mood. The device is designed to be used ...
Eric Leuthardt has contributed to two recently published studies showing proof that brain-computer interface therapy with the IpsiHand benefits the brain's motor networks and also motor recovery in chronic stroke patients with extended usage. ...
Andres Lozano, O.C., M.D., Ph.D., F.R.C.S.C., F.R.S.C., F.C.A.H.S., Principal Investigator at the Krembil Brain Institute, University Health Network states, “with this surgery, our objective is to use authentic cells, to have them integrate into the brain and restore lost physiologic function. ...
“The NRTX-1001 preclinical data package is compelling, supporting clinical development of a novel cell therapy designed to provide targeted inhibition to hyperexcitable neural networks in the epileptic brain,” said Dr. Blum. “With recent IND clearance from the U.S. ...
Relivion® is the first non-invasive multi-channel brain neuromodulation system for at home treatment of acute migraine, a debilitating neurological disease impacting 39 million people and resulting in 1.2 million emergency department visits annually. ...
Relivion® is a non-invasive brain neuromodulation* device that is placed around the head and delivers unparalleled stimulation to the occipital and trigeminal nerves. This creates a cumulative effect by releasing neurotransmitters in the brainstem and modulating brain networks associated with control of pain and mood. The device is designed ...
Neurolief, a neurotechnology innovator, today announces findings of the RIME US pivotal trial that demonstrate the safety and efficacy of the Relivion®, a novel external brain neuromodulation system for self-administered treatment of migraine. ...
Neurolief, a medical neurotechnology innovator, today announces that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Relivion®DP system, the first non-invasive multi-channel brain neuromodulation technology, for the treatment of major depression. ...